TheraRadar
Data updated: May 26, 2026

RHUZDAH (ethinyl estradiol)

Women's Health Approved 2022-10-11
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Discontinued
First Approved
2022-10-11
Routes
ORAL-28
Dosage Forms
TABLET

Companies

Active Ingredient: ETHINYL ESTRADIOL , NORETHINDRONE

RHUZDAH Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2022 to 2022
Oct 2022 ORIGINAL
Update

What RHUZDAH Treats

1 FDA approvals

Originally approved for its first indication in 2022 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 not yet recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

RHUZDAH FDA Label Details

Track RHUZDAH with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.